Healthcare and Insurance Sector Image

Healthcare & Pharmaceuticals

Effective advice built on strong foundations

Healthcare and pharmaceutical companies come to our law firm not just because we have the right expertise or the best people, but because we put in the work it takes to understand the sector.

With scientific advances, ever-changing government regulation, as well as strict ethical considerations, navigating healthcare legislation is rarely straightforward. So we make sure our legal advice is based on a comprehensive knowledge of current developments in the industry. We scour the legal and commercial developments in pharmaceuticals and in medicine as they happen, and we host annual seminars for our clients so that they, and we, can stay at the cutting edge.

Areas of law we advise pharmaceutical and healthcare clients on include intellectual property, regulation, commercial, competition and corporate law. We know that sometimes you will have to move fast to get a deal done, or to respond to an issue, so we focus on making sure you get a straight answer quickly.

Our lawyers advise companies working in:

  • Pharmaceuticals – including originators and generics
  • Biotechnology
  • Research and development
  • Medical devices
  • Health insurance
  • Health services provision
  • Hospitals and medical facilities
  • Aged care and retirement villages.

Show moreShow less

We also advise private equity firms, investors and financial advisers to the sector.

Our recent work in the healthcare and pharmaceuticals sector includes advising:

  • Cardinal Health in its US$470 million acquisition of Zuellig Pharma China, a private company and the largest drug importer in China
  • Genzyme, the world’s third largest biotech firm, on the establishment of a research and development wholly foreign-owned enterprise (WFOE) in Beijing
  • Fresenius Medical Care Asia Pacific on acquiring a leading Chinese pharmaceutical company
  • Ranbaxy on its successful application for a declaration of non-infringement against AstraZeneca in relation to the marketing of generic escitalopram
  • NicOx SA on a worldwide distribution and licensing deal with Rapid Pathogen Screening
  • An Israeli-Swiss pharmaceuticals group on its licence-out and grant of distribution rights for a drug for treatment of insomnia
  • A private UK company on the 2013 confidential acquisition of a number of FDA marketing authorisations from a major generic company
  • CVC Asia Pacific and Ironbridge on the AUS$1.4 billion sale of the Affinity Health hospitals to Ramsay Health Care Public Private Partnerships
  • Infrashore on the negotiation and preparation of soft and hard facilities management contracts for the Royal North Shore Hospital Redevelopment PPP and on issues arising during a dispute over staffing levels
  • The project financiers of the recently built Gold Coast University Hospital.
"The firm was thoroughly professional and supportive at all times. Their advice was detailed and sound, but also extremely practical at the same time."

Chambers
 

See our Life Sciences & Healthcare Update and Alert for the latest news and insights across the EU.

We advise clients working in the following sectors:

We have a full team specialising in this area.

Discover our latest insights into legal issues affecting your business

In order to minimise pressure on health spending, regulators around the world are increasingly looking to promote the availability of ‘biosimilars’ - biological products that are highly similar to...

05 October 2018

On 21 September 2018, the Victorian Supreme Court dismissed an appeal by the Commissioner of State Revenue (Commissioner) in Commissioner of State Revenue v The Optical Superstore Pty Ltd [2018] VSC...

28 September 2018

Australia’s new Prime Minister, Scott Morrison has promised the long awaited Indonesia-Australia free trade agreement by Christmas. The announcement is a good news story for international trade in...

05 September 2018

IP Australia has released an exposure draft for the proposed Intellectual Property Laws Amendment Bill which proposes several key changes to Australia’s patent laws

31 July 2018